← Back to Screener
Tiziana Life Sciences Ltd. Common Shares (TLSA)
Price$1.21
Favorite Metrics
Price vs S&P 500 (26W)-47.96%
Price vs S&P 500 (4W)-7.01%
Market Capitalization$147.38M
All Metrics
Book Value / Share (Quarterly)$0.08
P/TBV (Annual)10.35x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.07
Price vs S&P 500 (YTD)-20.92%
EPS (TTM)$-0.11
10-Day Avg Trading Volume0.20M
EPS Excl Extra (TTM)$-0.11
EPS (Annual)$-0.17
ROI (Annual)-305.91%
Cash / Share (Quarterly)$0.06
ROA (Last FY)-145.20%
EBITD / Share (TTM)$-0.16
ROE (5Y Avg)-404.34%
Cash Flow / Share (Annual)$-0.01
P/B Ratio16.02x
P/B Ratio (Quarterly)20.41x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-1539.00x
ROA (TTM)-92.11%
EPS Incl Extra (Annual)$-0.17
Current Ratio (Annual)1.02x
Quick Ratio (Quarterly)1.65x
3-Month Avg Trading Volume0.24M
52-Week Price Return39.33%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.05
52-Week High$2.60
EPS Excl Extra (Annual)$-0.17
26-Week Price Return-39.22%
Quick Ratio (Annual)1.01x
13-Week Price Return-15.65%
Total Debt / Equity (Annual)0.03x
Current Ratio (Quarterly)1.72x
Enterprise Value$140.232
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.03
3-Month Return Std Dev83.00%
Net Income / Employee (TTM)$-2
ROE (Last FY)-319.56%
Net Interest Coverage (Annual)-4.42x
EPS Basic Excl Extra (Annual)$-0.17
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$-0.11
ROI (TTM)-192.39%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.05
Price vs S&P 500 (52W)4.23%
Year-to-Date Return-16.78%
5-Day Price Return7.83%
EPS Normalized (Annual)$-0.17
ROA (5Y Avg)-135.30%
Month-to-Date Return5.98%
Cash Flow / Share (TTM)$-0.15
EBITD / Share (Annual)$-0.17
LT Debt / Equity (Annual)1.24x
ROI (5Y Avg)-287.29%
LT Debt / Equity (Quarterly)1.24x
EPS Basic Excl Extra (TTM)$-0.11
P/TBV (Quarterly)10.35x
P/B Ratio (Annual)19.57x
Book Value / Share (Annual)$0.04
Price vs S&P 500 (13W)-18.51%
Beta0.13x
Revenue / Share (TTM)$0.00
ROE (TTM)-195.51%
52-Week Low$0.76
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
TLSATiziana Life Sciences Ltd. Common Shares | — | — | — | — | $1.21 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Tiziana Life Sciences is a clinical-stage biotechnology company developing immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's lead candidate, Foralumab (a fully human anti-CD3 monoclonal antibody), is in development for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's disease, and other CNS indications. Its pipeline also includes programs for ALS.